Further Tests for Tumour-Initiating Activity: N,N-DI-(2-Chloroethyl)-P-Aminophenylbutyric Acid (CB1348) as an Initiator of Skin Tumour Formation in the Mouse by Salaman, M. H. & Roe, F. J. C.
363
FURTHER TESTS FOR TUMOUR-INITIATING ACTIVITY:
N,N-DI-(2-CHLOROETHYL)-P-AMINOPHENYLBUTYRIC ACID
(CB1348) AS AN INITIATOR OF SKIN TUMOUR FOR-
MATION IN THE MOUSE
M. H. SALAMAN AND F. J. C. ROE
From the Cancer Research Department, London Hospital Medical College, London, E.1
Received for publication April 17, 1956.
In previous papers (Salaman and Roe, 1953; Roe and Salaman, 1954, 1955),
it has been shown that there exist substances which, though not carcinogenic for
mouse skin, produce a change in this tissue such that a subsequent short course of
croton oil applications, insufficient to produce more than a few tumours in
previously untreated skin (Roe, 1956b), elicits tumours in considerable numbers.
This change was considered to be a form of incomplete carcinogenesis. In
accordance with accepted terminologies (Friedewald and Rous, 1944; Furth,
1953) such substances were called "tumour-initiators ".
Urethane (ethyl carbamate), 1, 2-benzanthracene, triethylene melamine (TEM),
and P-propiolactone have been shown to be tumour-initators for the skin of the
mouse. Two derivatives of urethane (ethyl N-phenylcarbamate and ethyl N-
methylcarbamate) showed similar activity, but the results required confirmation
(Graffi etal., 1953; Salaman and Roe, 1953; Roe andSalaman, 1955).
In the cases ofurethane, and TEM, application to the skin in near-lethal doses
without croton oil gave rise to no tumours (nor to any recognisable histological
change in the skin); and it was concluded that these substances are non-carcino-
genic for mouse skin. On the other hand both gave rise to tumours of mouse
lung, and TEM has been shown to give rise to sarcomata when injected sub-
cutaneously in the rat (Walpole et al., 1954). 1,2-Benzanthracene is probably
very weakly carcinogenic for mouse skin and other tissues (see Steiner and
Falk, 1951, for a review ofthe evidence); but in contrast to its weak carcinogenic
action, its tumour-initiating action is strong. 3-Propiolactone, which had not
been tested for carcinogenicity in mouse-skin at the time its tumour-initiating
effect was described (Roe and Salaman, 1955), has subsequently been found to be
weakly carcinogenic for this tissue (Roe and Glendenning, 1956). It had
previously been found to give rise to sarcomata following subcutaneous injection
in the rat (Walpole et al., 1954). As in the case of 1,2-benzanthracene, the
tumour-initiating action ofP-propiolactone in mouse skin is considerably stronger
than its carcinogenic action.
It was suggested (Roe and Salaman, 1955) that there might be a relation
between tumour-initiating activity for mouse skin and tumour-inducing activity
for mouse lung.Ureth ane, TEM, and ethyl N-methylcarbamate possess both
activities; 1,2-benzanthracene definitely possesses the first and possibly the
second; many other substances were shewn to be without either action (including
Myleran and colchicine). At the time this suggestion was made it was not knownM. H. SALAMAN AND F. J. C. ROE
whether 3-propiolactone gave rise to tumours in mouse lung. More recently
it has been found that intravenous injections of this substance (1 to 10 mg.)
failed to increase the incidence of lung tumours in mice (Roe and Glendenning,
1956). It seems therefore that there is no simple correlation between these two
activities. There is at present no clear indication of the chemical basis of
tumour-initiating action, and no evidence for a definite relation between tumour-
initiation and any other biological activity, except perhaps carcinogenicity for
other tissues or species (Roe and Salaman, 1955).
The present paper describes the results of tests of a further 20 substances for
tumour-initiating action, and a third test of ethyl N-phenylcarbamate (phenyl-
urethane), which gave doubtful and negative results respectively on two previous
occasions (Roe and Salaman, 1955, pp. 191 and 201). Reasons for the choice
of the 20 substances are briefly outlined below.
Selection ofsubstances
A list of substances screened is given in Table I. It was found convenient to
divide them into four classes: polycyclic hydrocarbons, aromatic nitrogen mustards,
purine analogues, and miscellaneous substances.
In the first class four substances were chosen for test, either because they were
thought to be on the borderline between carcinogenicity and non-carcinogenicity,
or because they were the parent substances of potent carcinogenic agents. As
pointed out above the tumour-initiating action of 1,2-benzanthracene is'far
stronger than its carcinogenic action, and it was thought possible that the same
might be true for other polycyclic hydrocarbons.
Anthracene has been tested for carcinogenicity by many workers, but never
with a positive result. Kennaway (1924a), who pointed out that workmen
handling purified anthracene do not suffer from skin lesions, failed to produce
skin tumours in mice with this substance (see also Kennaway, 1924b; Kennaway
and Hieger, 1930). Barry et al. (1935), and later Bachmann et al. (1937), painted
mice twice weekly with anthracene in benzene for 88 and 104 weeks respectively,
and failed to produce tumours. Boyland and Burrows (1935) injected anthracene
in colloidal solution subcutaneously into rats, but observed no tumours. Steiner
(1955) injected mice subcutaneously with anthracene in tricaprylin, with a similar
result. Demerec (1948) stated that anthracene was probably mutagenic for
Drosophila, but subsequently withdrew this statement (Demerec, 1949, quoted by
Auerbach, 1949).
Deoxycholic acid.-Occasional epitheliomata have been seen in mice painted
with deoxycholic acid repeatedly over long periods (Bachmann et al., 1937;
Badger et al., 1940; Cook, Kennaway and Kennaway, 1940), and subcutaneous
injection into mice has given rise to sarcomata after a prolonged period (Badger
et al., 1940). Klein (1952) found that deoxycholic acid applied to the skin gave
rise to no tumours either when used alone or in conjunction with croton oil.
Deoxycholic acid has been found to be mutagenic for bacteria (Witkin, 1947;
Jensen et al., 1951), and for Drosophila by Demerec (1948), but not by Jensen
et al., (1951).
Phenanthrene has been tested for carcinogenicity both on mouse-skin
(Kennaway 1924a, 1924c; Kennaway and Hieger, 1930) and also by subcutaneous
injection into mice (Steiner, 1955). No tumours have been recorded in any of
364TUMOUR-INITIATING ACTIVITY: "CB1348" AS AN INITIATOR
cti to to
o oo r
C0 00 0- *E _ e C
(M es
,-- Cq -
mE c-
g
O
S ' ]U-
.' ,
cr m~~~~~~~~~~~~~~~~~~~~~~~-
lfl'
=
(D ~ ~
S s G)~~
c2
E Q
L *
I.~~~~~~
0z
zz
ce co
xna
ei cc<Z o S e C
°-
z0 g ~ 9
0~ ~ ~ ~ ~ ~ ~~~~ ~~ ~ ~ ~ ~ C
.@" ~ ~ $o
* *
O r*-
0C0
0
~z
o ,
0
o ^ o
r44
5
*-4a 0Q 0
* .P .2
^ '_' ~'~
·
W S xo
tO
_
~ b
o
i10 10 HE
I.
365M. H. SALAMAN AND F. J. C. ROE
- eq 0 X0 cO eq q eq co eq c m r
eq 1
cq - eq o qc cq eq eq c0 co r
CO CO CO 0 0 1 CO d4 - Co t- 0 Co
eq eq eq - - - eq - cq - - - eq r-
0 0 0
m 02
10
10
C0
m
. -
* *
COm 10 CO eq eq eq
*
I 02
4)
o
eq C0 to
eq eq eq
I'0i I-8 -> i-> X z ^ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~C
$ : 3 n .o n$$ i
10 7~~~~)
'o 0 o 0 0
0 8
a) } 8 m 8°2 a
EH o ti w s o@e o9w 0 04 _, _l _l _, ec _l
v
0
0 0
.-I ~
.~c ',Q '4; +0Ca
-4 P-
o o
b~~~~~~~b
c~
D =
X -
D~~~~~
0t
4o
· o
o e
C)
o eq -
cge _C.
0 -- -
bE
Ce
bO
O CO
0 0
bb
o CO
b
CO
eq ~0 Cq CO
0 c·
0~~~~~~~
. * · *.
. . .0
0
o ~ o2 o
...0 · _
4 e
10 to O 0 0 o -
- - - eq eq
366
m 02
CO
0
02
O
-_
an I I
I I
C) C)
04 0-4
04 P4
8a)
o
,,o
o D
0,
4)0C 0
C)
-4 04
-4TUMOUR-INITIATING ACTIVITY: "CB1348 AS AN INITIATOR 367
000
i E-1
o b
+C 0 0*~0 - o 0
14
0
14~~~~~~~~~~~~~~~~~~~1
0 0
O O
,
· .
0 ,.
"le .0
qD *
Itt ~~~~0
~~~~~~1 0
H
P
- '-
*c
0 0
0
0
0a 0
rn 0
._
0 °m wb
.9 0
CD
0
0 0
0 - -4
0 0
0 9 0 0 0 0
0 4a 4z
-+l. 0 0
0~~~~~~~~
4 O O
0 a 14i 1
14 C) C)
C) -
C) C) C)
0 0
*4 >
25
IM. H. SALAMAN AND F. J. C. ROE
these tests. Graffi et al. (1953) applied phenanthrene and croton oil alternately
to the backs of mice for a year; the yield of tumours was not significantly higher
than in croton oil controls. Demerec (1948) found phenanthrene to be non-
mutagenic for Drosophila.
Pyrene.-Occasional papillomata have been seen on mouse skin following
repeated applications of pyrene by Barry et al. (1935), but not by Badger et al.
(1940). Graffi et al. (1953) tested pyrene in the same way as phenanthrene (see
previous paragraph); the result was again negative. Demerec (1948) found it
to be non-mutagenic for Drosophila.
The second class consisted of three aromatic nitrogen mustards. The first of
these. N,N-di-(2-chloroethyl)-p-aminophenylbutyric acid (CB1348), was synthesized
by Everett, Roberts, and Ross (1953). It was found to have a more powerful
tumour-inhibitory effect on the Walker rat carcinoma 256 than several hundred
other biological alkylating agents, including a series of closely related mustards.
(Ross et al., 1952). Galton et al. (1955) reported striking remissions in patients
suffering from Hodgkin's disease, lymphocytic lymphoma, chronic lymphocytic
leukaemia, and follicular lymphoma, as a result of treatment with CB1348.
Haddow (personal communication) injected a group of male rats subcutaneously
weekly for 12 weeks with CB1348 in arachis oil. A sarcoma arose at the injection
site in one out of 12 rats one year after the last injection. A sarcoma at the
injection site was also seen in one of a group of 12 mice similarly treated.
Since it is not unknown for sarcomata to arise following injection of arachis oil
only (Walpole et al., 1954) the carcinogenicity of CB1348 remains in doubt.
CB1348 was found by Fahmy and Fahmy (1952) to be mutagenic for Drosophila,
and by Gopal-Ayengar (1952) to produce chromosome abnormalities.
The other two substances of this class are the two isomers p-di-(2-chloroethyl)-
amino-L-, andD-phenylalanine. The synthesis ofthese substances was described
by Bergel and Stock (1954). The same authors (1953) reported a remarkable
difference in the tumour-inhibitory effects of the two isomers on the Walker rat
carcinoma 256, the L-form showing strong inhibition of growth and the D-form
only slight activity. Bergel et al., (1954) state that their colleagues, Dr. Elson and
Professor Koller, have found similar differences in the effects of the two isomers
on the blood picture of the normal rat, and in the production of chromosome
abnormalities.
The isomers have not been tested separately for carcinogenicity, but in an
experiment (Haddow: personal communication) in which the racemic mixture
was injected subcutaneously in arachis oil weekly for 12 weeks into 10 female
rats, a sarcoma arose at the injection site in one rat 18 months after the final
injection. Two out of 20 mice, similarly treated, developed sarcomata at the
injection site. For the reason stated in the case of CB1348 this result is also
indecisive. Fahmy and Fahmy (1953; and personal communication) found
that both the D- and L-forms were mutagenic.
The third class consisted of four purine analogues. Three of them have been
shown to have tumour-inhibitory or antileukaemic effects: 2,6-diaminopurine
(2,6-DAP) by Burchenal et al. (1949) and Skipper et al. (1950); 6-mercaptopurine
(6-MIP) by Clarke et al. (1953), and Burchenal et al. (1953); and 8-azaguanine
(8-AG) by Kidder and Dewey (1949), Gellhorn et al. (1950), and Law (1950). It
will be recalled that two known tumour-initiators, urethane and TEM (Roe and
Salaman, 1955), also possess these properties. 2,6-DAP and 6-MP have both
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beenii shown to induce chromosome abnormalities, the former in mice by Dustin
(1950), and the latter in Allium and Pisum by Kihlman (1952). 8-AG was
found by Novick and Szilard (1951) to be mutagenic for E. coli.
2,6-Diamino-8-phenylpurine, a purine analogue recently synthesized by Mr.
G. M. Timmis ofthe Chester Beatty Research Institute, was also tested. Little is
known of its biological activity at present.
The fourth class consisted of 10 miscellaneous substances, which were chosen
for test for a variety of reasons.
Phenylurethane, chemically and pharmacologically related to urethane, had
been tested twice before, with a doubtful and a negative result respectively (Roe
and Salaman, 1955). The properties of this substance were discussed in that
paper. In those tests 0-5 g. and 1.32 g., respectively, were applied. In the test
described below a total of 1.8 g. was applied.
Potassium arsenite, the active constituent of Fowler's solution, was selected
because of its antileukaemic action. It was first used in the treatment of
leukaemia by Valentiner (1865), and Lissauer (1865), but went out offashion with
the introduction of radiotherapy. Forkner (1938) reintroduced it, and Flory
et al. (1943) found it efficacious in several strains of mouse leukaemia. Skipper
et al. (1951) found that potassium arsenite, like urethane, nitrogen mustard, folic
acid antagonists, and certain purine analogues (including 2,6-DAP and 8-AG),
inhibited the incorporation of labelled formate in the synthesis of nucleic acid
purines. Warren (1943) found that arsenite depressed respiration and, probably
as a secondary effect, accelerated aerobic glycolysis (urethane also inhibits aerobic
glycolysis: Quastel and Wheatley, 1933, 1934). Piton (1929) found that potas-
sium arsenite stimulated mitosis in the intestinal epithelium of the mouse, but
that this was followed by death ofthe mitotic cells. Leitch and Kennaway (1922)
painted mice thrice-weekly with a 0.12 per cent solution of potassium arsenite in
ethanol, and observed an epithelioma and a benign wart in 1 out of the 30 mice
which survived for 3 months or more. The epithelioma had metastasised to the
lung. Askanazy (1926) records the development of stomach neoplasms in 4
rats after prolonged administration of potassium arsenite in the drinking water.
Cholewa (1935) observed lung tumours in mice given potassium arsenite by mouth,
and a sarcoma of the ear in one of two rabbits injected subcutaneously with the
substance. Evidence for the carcinogenicity of potassium arsenite, and other
arsenical compounds, for both man and experimental animals, is reviewed and
discussed by Neubauer (1947).
Three substances, aspirin, saccharin, and vanillin, were chosen for no other
reason than that they are commonly ingested. Hartwell (1951) lists four experi-
ments in which aspirin was tested for carcinogenicity in rats; in three the sub-
stance was given by mouth, and in one subcutaneously in lard. No tumours
were seen in any of these experiments. Fitzhugh, Nelson, and Frawley (1951)
reported an increased incidence of abdominal lymphosarcomata in rats fed for
102 weeks or more on a diet contain 5per cent saccharin, butthe number ofanimals
involved was small (4 with abdominal lymphosarcomata among 18 rats which
survived for 1 year or more). Vanillin has apparently not been tested for
carcinogenicity.
Acrolein, an unsaturated aldehyde (CH2 CH.CHO), was chosen mainly
because it is actively mutagenic for Drosophila (Rapoport, 1948). Steiner,
Steele, and Koch (1943) injected 15 mice subcutaneously weekly for 24 weeks withM. H. SALAMAN AND F. J. C. ROE
acrolein in sesame oil. There were 11 survivors at 12 months, but no tumours
were seen.
Diethyl carbonate was chosen for test because of the similarity of its molecular
structure to that of urethane.
OC2H5 OC2H5
0 = C 0 = c
NH2 OC2H5
Urethane. Diethyl carbonate.
This substance has apparently not been tested for carcinogenicity on mouse-skin,
mouse-lung, or other tissues.
8-Hydroxyquinoline was chosen for test on account of its powerful chelating
action. No substance with this type of chemical action was included in our
previous series (Salaman and Roe, 1953; Roe and Salaman, 1955).
Monosodium maleic hydrazide was found to exert a growth-inhibitory effect on
certain plants by Schoene and Hoffmann (1949), Wittwer and Sharma (1950), and
White (1950); and its possible use as a selective herbicide was suggested by
experiments of Currier and Crafts (1950). Darlington and McLeish (1951) found
that low concentrations of maleic hydrazide ( <0.0005 M) caused chromosome
breaks in the roots of Vicia; exposure to higher concentrations for 24 hours
inhibited mitosis entirely for 2 days. Loveless (1953) tested a series ofcompounds
related to maleic hydrazide (including uracil, thymine, and orotic acid), but
failed to observe chromosome-breaks in Vicia. Haddow, Koller, and Waymouth
(in a private communication to Loveless, 1953) state that they found no evidence
that maleic hydrazide gives rise to chromosome-abnormalities in animal tissues,
either in vivo or in vitro. The substance is beiniig tested for carcinogenicity at
present (Haddow, personal communication).
Oxalacetic acid was chosen for test because of a report by Rogers (1954), who
found that the simultaneous administration of oxalacetic acid with urethane to
mice considerably increased the incidence of lung tumours due to the latter.
In view of the possible relation between initiating action for mouse skin and lung
tumour induction (Roe and Salaman, 1955) it was thought advisable to test
oxalacetic acid for initiating action.
MATERIALS AND METHODS
Mice
These were of the " S " strain as used in previous screening experiments.
(Salaman and Roe, 1953; Roe and Salaman, 1955).
Chemical substances and solvents
The four substances ofClass I 2, 6-diaminopurine, acrolein, oxalacetic acid, and
vanillin, were obtained from L. Light and Co. Ltd.
Professor F. Bergel (of the Chester Beatty Research Institute) kindly supplied
the three substances of Class II and diethyl carbonate. Professor E. Boyland
and Mr. G. M. Timmis (of the same Institute) kindly supplied monosodium
maleic hydrazide, and 2,6-diamino-8-phenylpurine and 6-mercaptopurine,
respectively.
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8-Azaguanine was obtained from Cyanamid Products Ltd., Lederle
Laboratories Division.
Aspirin, 8-hydroxyquinoline, ethyl N-phenylcarbamate (phenylurethane),
potassium arsenite, and saccharin, were obtained from British Drug Houses, Ltd.
Croton oil.-Two batches (Batches I and II) of oil were used. Both were
supplied by Messrs. Stafford Allen. They had been prepared by simple expression
ofthe seeds ofCroton tiglium, at different dates. Batch II was more irritant than
Batch I, and was used at a lower concentration. In other respects the two batches
of oil appeared similar (Roe, 1956b).
Solvents.-Either acetone (AR grade, British Drug Houses Ltd.) or methanol
(James Burrough, Ltd.) was used for all substances, except those of Class III and
monosodium maleic hydrazide; for the latter four substances 50 per cent aqueous
carbowax 300 (polyethylene glycol ofaverage molecular weight 300, obtained from
General Metallurgical and Chemical Co., Ltd.) was used.
Methods
The techniques of application of solutions, recording of tumours, examination
of mice for lung adenomas at post-mortem, and histological examination, have
been fully described (Roe and Salaman, 1955).
The choice of dose and of dose-schedule for individual test substances was
governed by two factors: solubility in a suitable solvent, and toxicity. Non-
toxic substances were applied at the highest concentration obtainable in a suitable
solvent, thrice weekly until 10 applications had been given. Toxic substances
were applied 10 times at weekly intervals, at the highest tolerated concentration.
In all cases (except that of pheny]urethane) croton oil treatment was begun
between 22 and 30 days after the first application ofthe test substance.
Further details ofthe dose-schedules for individual substances are given below
and in Table I.
EXPERIMENTAL
Three lots of mice, obtained at different times from the same animal-breeder,
were used. From each lot 20 control mice were selected at random to be treated
with croton oil only: these will be referred to as control groups A, B, and C,
respectively. The remaining mice of each lot were divided into groups of 14 to
25 mice, for treatment with the test substances followed by croton oi].
Treatment with croton oil differed slightly for the three lots of mice. The
first lot, including control Group A, received 18 weekly applications of 0.5 per
cent Batch I oil (see p. 371). The second batch of mice, including control
Group B, received one application of Batch II oil at a concentration of 0-17 per
cent; this caused moderate ulceration in many ofthe mice, and the concentration
of the 2nd and 3rd weekly applications was reduced to 0.085 per cent; thereafter
0-17 per cent was given and well tolerated for a further 15 weekly applications
(making 18 weekly applications in all).
The control group of the third lot of mice, Group C, received 18 weekly
applications of 0.17 per cent Batch II croton oil; but the concentration of the
first two applications of croton oil given to the corresponding test groups was
0.1 per cent.
In the case of the less toxic test substances 10 thrice-weekly applications were
given at concentrations near saturation in acetone, methanol, or 50 per cent
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aqueous carbowax 300. In these groups croton oil treatment was not begun until
treatment with the test substance had been completed. Applications ofthe more
toxic substances were separated by weekly intervals, andthe earlier applications
of croton oil alternated at 3- to 4-day intervals with those ofthe test substance.
Details of treatment are given in Table I. Those tests in which treatment with
croton oil overlapped that with the test substance are marked with an asterisk.
Because of the low solubility of anthracene (Group 1) at each of the 10 treat-
ments (thrice weekly) two applications of 0 3 ml.0 5 per cent were given, separated
by an interval of 30 minutes.
The toxicity of the three aromatic nitrogen mustards (Groups 5 and 7)
necessitated a close watch on the condition of the mice during treatment. A fall
in average body weight was taken as an indication to reduce the dose. Details of
dosage' are given in Table I.
8-Hydroxyquinoline (Group 15) proved too toxic at the concentration tested
(0-5 per cent) for more than 6 weekly applications to be given.
In the case of phenylurethane (Group 18) 2 applications (with an interval of
30 minutes) of 0.3 ml. 20 per cent w/v were given each week for 15 weeks. An
interval of 6 weeks followed in which no treatment was given. Thereafter a
course of croton oil treatment was begun. This course, it should be noted, was
given 17 weeks later than to the corresponding control group (Group A). The
long initial course of treatment with phenylurethane alone was intended as a
test for carcinogenicity of this substance: it was negative.
RESULTS
(A) Skin Tumour Production
Papillomata. Table I shows the numbers of survivors, of tumour-bearing
mice, and of tumours, one week after the end of croton oil treatment.
A few papillomata were seen in two out of three of the control groups treated
with croton oil only. In several ofthe test groups the incidence ofthese tumours
exceeded that in the corresponding control group. In some cases the difference
was marked, namely, deoxycholic acid (Group 2), phenanthrene (Group 3), pyrene
(Group 4), CB1348 (Group 5), the isomeric phenylalanine mustards (Groups 6 and
7), phenylurethane (Group 18), and saccharin (Group 20). Statistical analysis
of the results by the t-test, however, showed that only in the cases of CB1348
(Group 5) and phenylurethane (Group 18) are the differences significant: the
test for the difference between the mean numbers oftumours per mouse in Groups
5 and C gives t - 3.07 on 34 degrees of freedom (d.f.), P < 0-01; that between
Groups 18 and A gives t = 2.33 on 32 d.f., 0-05 > P > 0-01.
Malignant tumours.-Shortly after the end of croton oil treatment all mice,
except those of Groups B and C and a few papilloma-bearing mice of Groups 5
(6 mice), 6 (3 mice), and 7 (5 mice), were killed and examined post mortem for
lung adenomata (see below). Mice of Group C continued to receive weekly
applications of 0.17 per cent Batch II croton oil; the subsequent development of
further tumours in this Group has been reported elsewhere (Roe, 1956b; Group 5).
Mice of Group B, and those of Group 5, 6, and 7 which were not killed at the end
of croton oil treatment, were kept without further treatment and examined
weekly for the development of malignant tumours of the skin.
So far no definitely malignant tumour has been seen in Group B. However
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there has been one tumour which arose as a subcutaneous nodule and later (8
months after the end of croton oil treatment) became ulcerated. A biopsy was
taken from this tumour 10 days after ulceration was first observed.
Microscopically it appeared to be an epithelioma oflow-grade malignancy; it had
infiltrated the dermis and extended down to the panniculus carnosus, but at no
place was infiltration of this muscle layer seen. The mouse died two weeks after
biopsy, further sections of the tumour still showed no infiltration of the muscle
layer. This tumour is regarded as "probably malignant" (Roe, 1956a).
One of the 5 mice retained from Group 7 (L-phenylalanine nitrogen mustard
and croton oil) which was kept under observation developed an undifferentiated
carcinoma. This tumour first appeared malignant 3 weeks after the end of
croton oil treatment. Histologically it showed penetration of the panniculus
carnosus (Fig. 1 and 2) and there was a metastasis in the regional lymph node.
One of the 3 mice retained from Group 6 (D-phenylalanine nitrogen mustard
and croton oil) developed a squamous carcinoma 15 weeks after the end of croton
oil treatment. Histologically this tumour also showed penetration of the
panniculus carnosus.
No malignant tumours have so far arisen in mice treated with CB1348 and
croton oil (Group 5).
Observation of the survivors of these groups is being continued.
It is concluded that both CB1348 and phenylurethane are effective initiators
of skin tumour formation in the mouse. The fact that other substances (deoxy-
cholic acid, phenanthrene, pyrene, saccharin, and the two isomeric phenylalanine
mustards) in conjunction with croton oil gave rise to more papillomata than
croton oil only, is of doubtful significance. On the other hand, the fact that a
malignant tumour arose in Group 6 and in Group 7 among the very few mice
kept for observation, suggests that the two isomeric phenylalanine mustards,
if given in higher dosage, might shew a significant tumour-initiating effect.
Anthracene, 4 purine analogues, and 8 miscellaneous substances, all gave negative
results.
(B) Histologicalfindings in the skin
Previously it has been shown that among a wide variety of substances tested
there is no correlation between the initiation of skin tumour formation and the
production of hyperplasia of the epidermis (Salaman and Roe, 1953; Roe and
Salaman, 1955). No correlation is found even within a group of substances
related to each other chemically and pharmacologically. For instance, among a
limited number of alkylating agents, nitrogen mustard (HN2) and R48 (N,N-di-
(2-chloroethyl)-3-naphthylamine) produced a characteristic type of epidermal
hyperplasia, but did not initiate tumour formation, TEM (triethylene melamine)
produced no recognisable change in the skin, but was an effective initiator, while
Myleran (1, 4-dimethane-sulphonoxybutane) was inactive in both respects.
The three aromatic mustards included in the present series were tested for
action on the skin. They were applied twice, with one week's interval, at a
concentration of 0-33 per cent (i.e. 3 times the highest concentration used in the
main experiment), and biopsy specimens of the treated skin were removed three
days after the 1st and 2nd applications.
CB1348 (0.33 per cent) caused a slight patchy epidermal hyperplasia, with
some cellular enlargement, and reduction in numbers of sebaceous glands. This
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effect was similar in character to that due to HN2 (0.2 per cent, Salaman and
Roe, 1953), but less in degree. Neither of the two phenylalanine mustards
(0.33 per cent) produced any recognisable changes in the skin.
(C) Incidence ofpulmonary adenomata
All mice except those of Groups B and C, and a few papilloma-bearing mice
in Groups 5, 6, and 7, were killed shortly after the end of croton oil treatment and
examinedpost mortem for lung adenomata.
Mice of Groups 6 and 7, treated with the dextro- and laevo-phenylalanine
mustards respectively, and croton oil, had a high incidence of lung tumours
(47 in 13 out of 18 mice examined, and 55 in 11 out of 13 mice examined,
respectively). The highest incidence observed among the other test groups was
in Group 5, treated with CB1348 and croton oil (13 in 7 out of 12 examined),
and in this case the incidence is only slightly above that seen in untreated mice of
the same strain (unpublished data).
Applications of croton oil to the skin are not now believed to increase the
incidence of pulmonary tumours in mice (Roe, 1956b), though at one time (Roe
and Salaman, 1955) it was thought that they might do so. In the present experi-
ment the incidence of lung tumours in mice of Group A, treated with croton oil
only, was 17 in 10 out of 17 mice examined.
It is concluded that the high incidence of lung tumours in mice of Groups 6
and 7 resulted from treatment with the phenylalanine nitrogen mustards.
DISCUSSION
The present series of tests for initiating action extends previously reported
series (Salaman and Roe, 1953; Roe and Salaman, 1955), using similar methods.
The substances chosen for test fall into 4 classes: polycyclic hydrocarbons,
aromatic nitrogen mustards, purine analogues, and miscellaneous. The last
class contains some commonly used drugs and food additives, and some substances
chosen either because of reported doubtful carcinogenicity, or because of their
chemical relation to other initiators.
Only two substances, phenylbutyric acid nitrogen mustard (CB1348) and
phenylurethane, initiated the development of tumours in significantly higher
numbers than in corresponding control groups. In six other cases (deoxycholic
acid, phenanthrene, pyrene, thedextro- andlaevo-phenylalanine nitrogen mustards,
and saccharin) tumour incidence was higher than in controls, but the differences,
though suggestive, are not significant by accepted standards.
There is no reasonto abandonthe view previously expressed (Roe and Salaman,
1955), that substances which initiate tumour development in the skin are either
carcinogenic for both the skin and other tissues (e.g. 3, 4-benzpyrene and the other
EXPLANATION OF PLATES
FIG. 1.-Carcinoma arising from the dorsal skin of a mouse treated with L-phenylalanine
nitrogen mustard and croton oil (Group 7). The tumour, which first appeared to be malig-
nant 3 weeks after the end of croton oil treatment, has penetrated the panniculus carnosus.
[Stain: Haematoxylin and eosin-Biebrich scarlet (Salaman and Gwynn, 1951); x 16.]
FIG. 2.-Higher power view of tumour shown in Fig. 1. Carcinomatous tissue can be seen
separating the striated muscle fibres of the panniculus carnosus. [Stain: as Fig. 1;
x 350.].
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carcinogenic hydrocarbons) or for tissues other than the skin [e.g. urethane
(Salaman and Roe, 1955); and TEM (Roe and Salaman, 1955)]. There are
borderline cases however. Several substances of very weak or doubtful carcino-
gencity (e.g. 1,2-benzanthracene, see Steiner and Falk, 1951, for review) are
nevertheless powerful initiators of skin tumour formation (Graffi et al., 1953;
Roe and Salaman, 1955); and others, which show a low grade of initiating
activity, are either doubtful or very weak carcinogens (e.g. CB1348: Haddow,
personal communication; and methylurethane: Roe and Salaman, 1955;
Larsen, 1948), or have so far proved non-carcinogenic (e.g. phenylurethane: Roe
and Salaman, 1955 and present paper, p. 372). The fact that there are such
borderline cases should not lead to the abandonment of the hypothesis that
there is a correlation between tumour-initiating activity in skin and carcino-
genicity for skin or some other tissue. More evidence is required, and factors of
dosage, and rapidity of detoxication and excretion, must be considered, before a
decision can be reached on this question.
On the other hand, the suggestion that there is a correlation between initiating
action in skin and adenoma production in lung (Roe and Salaman, 1955) has not
been supported by the results now recorded. For instance, among the three
aromatic nitrogen mustards tested, CB1348 acted as an initiator for the skin but
did not significantly increase the incidence of lung adenomas, while both the
isomeric phenylalanine mustards markedly increased the incidence oflung adeno-
mas but were ineffective as initiators for the skin. Further, as has been mentioned
above, ,-propiolactone is an active initiator in skin but does not increase the
incidence of lung adenomas.
One of the most interesting findings in previous experiments was that a sub-
stance can be a powerful initiator of tumour development in the skin without
producing epidermal hyperplasia or anyother recognised histological change (e.g.
urethane: Salaman and Roe, 1953; TEM: Roe and Salaman, 1955). Among
the substances included in the present series, of the two which showed definite
initiating activity CB1348 caused very slight histological changes [similar in
nature to, but very much less marked than, those caused by HN2 or R48, neither
of which are initiators (Salaman and Roe, 1953)] and phenylurethane (like the
more powerful initiator, urethane) caused no detectable change whatever (Roe
and Salaman, 1955).
Phenylurethane produced no tumours when applied alone repeatedly to skin
(see p. 372). A corresponding test of CB1348 is not complete. All substances
or procedures at present known which "promote " tumour-development [e.g.
croton oil, iodoacetic acid, chloracetophenone (Gwynn and Salaman, 1953),
mechanicaltrauma (PulLinger, 1945)] produce epidermal hyperplasia, and it there-
fore seems probable that a complete carcinogen, in contradistinction to an
initiator, must have this property.
SUMMARY
1. A further 20 substances have been tested for tumour-initiating action on
mouse-skin.
2. Among 3 aromatic nitrogen mustards tested, one, NN-di-(2-chloroethyl)-
p-aminophenylbutyric acid (CB1348), was found to be an initiator of tumour
formation. The two others, p-di-(2-chloroethyl)-L- and -D-phenylalanriine, each
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gave rise to an incidence of papillomata which was not significantly higher than
the control level.
3. Four of the other substances tested, deoxycholic acid, phenanthrene,
pyrene, and saccharin, also gave borderline results.
4. Phenylurethane which gave borderline and negative results, respectively,
in two previous tests, gave a significantly positive result in a third test.
5. Anthracene, aspirin, vanillin, monosodium maleic hydrazide, and 4 purine
analogues, were among the substances which gave negative results.
6. A few papilloma-bearing mice from the groups treated with the 3 aromatic
nitrogen mustards, and the whole of a croton oil control group, were kept under
observation for 8 months after the end of treatment. A malignant epithelioma
appeared in both the L- and D-phenylalanine nitrogen mustard groups 3 and 15
weeks, respectively, after the end oftreatment. No malignant tumours were seen
in any other group.
7. The majority of mice were killed and examined for lung adenomata shortly
after the end of treatment. Among all the substances tested, only the dextro-
and laevo- phenylalanine mustards increased the incidence of these tumours.
8. The results are discussed.
We are grateful to Professor Bergel for suggesting the use ofdiethyl carbonate,
and the 3 aromatic nitrogen mustards, and to Professor Boyland for suggesting
the use of maleic hydrazide and saccharin.
We are indebted to Mr. J. G. Chapman, Miss 0. M. Glendenning, Mr. W. J.
Milton, Mr. J. A. Rawlings, and Mr. A. L. Stifffor their skilledtechnical assistance.
The expenses of this research were partly defrayed out of a block grant from the
British Empire Cancer Campaign.
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